Rezolute, Inc. (RZLT) · Oct 14, 2026 · Other events
Enrollment complete — 16-patient study fully enrolled; topline data expected mid-December 2026
Rezolute’s trial enrollment milestone keeps its tumor hyperinsulinism program on track, but December efficacy data still decide the story.
Rezolute is relying on ersodetug to build a two-indication hyperinsulinism franchise. Its congenital-HI regulatory path remains under FDA review, while the tumor-HI program is the next clean clinical catalyst; the company had already said on October 5 that upLIFT remained on track for data before year-end.
The filing removes execution risk, but not efficacy risk. The 16-patient Phase 3 upLIFT study is now fully enrolled, with topline results expected in mid-December 2026. 〔0〕 This is modestly better than simply remaining on schedule, but the timing was broadly expected, so the milestone itself does not settle the investment case.
The interim signal gives the final readout a relatively low hurdle, but the sample is tiny. Seven of the first eight participants met the responder criterion, and each discontinued intravenous glucose; however, the study needs at least 9 of 16 responders to reach the stated 56% response threshold implied by its statistical-success bar. 〔1〕 That means at least two of the remaining eight participants must respond, assuming the stated 16-participant denominator.
Safety is not currently the visible problem. Rezolute reports no drug-related safety findings so far, while the primary endpoint measures whether patients requiring intravenous glucose achieve at least a 50% reduction in glucose infusion rate. 〔2〕 The unresolved question is whether the small, single-arm dataset will produce a sufficiently robust efficacy result for a registrational and regulatory path.
Bottom line: This is a real progress milestone and keeps the tumor-HI program on schedule, but it mostly advances the story to its decisive moment. The meaningful update is still the mid-December efficacy readout, not enrollment completion itself.
upLIFT topline data, mid-December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!